Drug Alerts

  • Drug Alert 131
    pdf, 667kb

    Falsified antimalarial medicines in west and central Africa
  • Drug Alert 130
    pdf, 215kb

    Falsified batches of Coartem recently circulating in Cameroon
  • Drug Alert 129
    pdf, 85kb

    Contaminated Dextromethorphan active pharmaceutical ingredient
  • Drug Alert 128
    pdf, 63kb

    Falsified batches of Postinor 2 recently discovered in Nigeria
  • Drug Alert 127
    doc, 62kb

    Falsified batches of Coartem recently circulating in Western and Central Africa
  • Drug Alert 126
    pdf, 145kb

    Contaminated Dextromethorpan Active Pharmaceutical Ingredient
  • Drug Alert 125
    pdf, 43kb

    Contaminated Isotab® (isosorbide mononitrate) incident in Lahore Pakistan
  • Drug Alert 124
    pdf, 133kb

    A/H1N1 vaccination safety: new safety surveillance tool available
  • Drug Alert 123
    pdf, 50kb

    Dextropropoxyphene-containing medicines to be withdrawn from European market
  • Drug Alert 122
    pdf, 35kb

    Warning on purchase of antivirals without a prescription, including via the Internet
  • Drug Alert 121
    pdf, 147kb

    Marketing authorization of efalizumab in the European Union to be suspended due to safety concerns
  • Drug Alert 120
    pdf, 109kb

    Toremifene should not be used in patients at risk of QT-prolongation or other heart problems: recommendation from the European Medicines Agency
  • Drug Alert 119
    pdf, 67kb

    Marketing authorization for rimonabant to be suspended across the European Union since the benefits of the medicine do not outweigh its risks
  • Drug Alert 118
    pdf, 105kb

    Contaminant detected in heparin material of specified origin in the USA and in Germany; serious adverse events reported; recall measures initiated
  • Drug Alert 117
    pdf, 140kb

    Antimalarial chlorproguanil-dapsone (LapDap™) withdrawn following demonstration of post-treatment haemolytic anaemia in G6PD deficient patients in a Phase III trial of chlorproguanil-dapsone-artesunate (Dacart™) versus artemether-lumefantrine (Coartem®) and confirmation of findings in a comparative trial of LapDap™ versus Dacart ™
  • Drug Alert 116
    pdf, 104kb

    Veralipride (The European Medicines Agency (EMEA) has issued a Press Release recommending the withdrawal of the marketing authorization for all medicinal products containing veralipride).
  • Drug Alert 115
    pdf, 164kb

    Vincristine (chemotherapeutic agent)
  • Drug Alert 114
    pdf, 67kb

    (All batches of Viracept (nelfinavir) recalled from the European Market due to possible contamination with a genotoxic substance)
  • Drug Alert 113
    pdf, 69kb

    (Oral nimesulide: marketing suspended in Ireland due to reports of liver failure)
  • Drug Alert 112
    pdf, 76kb

    (Levaquin {levofloxacin} injection {25 mg/ml 20 ml vials, Batch Nos. 6CB5W00, 6CB6100; Expiry February 2008}: product likely intended for black market use; public health hazard)
  • Drug Alert 111
    pdf, 63kb

    (Cyclooxygenase-2 {COX-2} Inhibitor Medicines)
  • Drug Alert 110
    pdf, 71kb

    {Counterfeit triple antiretroviral combination product (Ginovir 3D) detected in Côte d’Ivoire}
  • Drug Alert 109
    pdf, 121kb

    {Virologic failure in HIV patients treated with the combination of Didanosine, Lamivudine and Tenofovir}
  • Drug Alert 108
    pdf, 109kb

    {Suspension of Manufacturing Licence held by Pan Pharmaceuticals Limited, Sydney}
  • Drug Alert 107
    pdf, 73kb

    {Important safety update on lepirudin (Refludan) following reports of fatal anaphylactic reactions}
  • Drug Alert 106
    pdf, 74kb

    {Risk of serious hypersensitivity and skin reactions with parecoxib sodium The European Medicines Evaluation Agency (EMEA) has issued a public statement}
  • Drug Alert 105
    pdf, 73kb

    {Olanzapine: associations with hyperglycemia resulting in diabetic ketoacidosis and coma}
  • Drug Alert 104
    pdf, 66kb

    {Rapid Alert Notification of a Quality Defect in Prednisolone- Gentamicin (Pred-G) Eye Drops}
  • Drug Alert 103
    pdf, 77kb

    {Nonacog alfa (Benefix) : Intensive post-marketing surveillance and new clinical trials for additional data}
  • Drug Alert 102
    pdf, 77kb

    {Voluntary withdrawal of Cerivastatin – Reports of Rhabdomyolysis}
  • Drug Alert 101
    pdf, 78kb

    {Leflunomide – severe and serious hepatic reactions}
  • Drug Alert 100
    pdf, 78kb

    {Infliximab (Remicade) – reports of tuberculosis infections}